HealthBIO Seminar,
Wednesday, 15 September 2021

Organized for the 15th time, Finland’s largest annual life-science event HealthBIO seminar will be held on the 15th of September in the Presidentti Auditorium of the Conference Center Mauno in BioCity.

This year’s program includes an overview of the newest trends, and successful companies will share their latest insights on the development of the life-science business environment. The program also introduces the most significant projects in the life-science field: CancerIO focusing on immune-oncology, and InFlames focusing on immunology. An update of the situation of the national Drug Development Centre will also be presented.
Link to the program:
HealthBIO 2021 Program

If you would like to be added to a waiting list for this event, please send email to

HealthBIO 2021 online Partnering Event,
Thursday, 16 September, 2021

Are you interested in partnering opportunities or investing in the life science companies? Registration to HealthBIO Partnering is now open!

Please notice that we decided to change the HealthBIO 2021 Partnering event into a digital event, due to the Covid-19 situation in Finland.

Partnering arrangements are coordinated by Enterprise Europe Network (EEN).

Register to the Partnering event and create your profile by the 12th of September here: HealthBIO 2021 Partnering



HealthBIO 2020, 4th November

Due to coronavirus situation, HealthBIO event was exceptionally arranged as an one-day hybrid event. Number of on-site attendees was limited to 25 persons, and more than 100 followed presentations online.


Finnish Biotech Year 2019-2020, Tero Piispanen, Turku Science Park Ltd
How COVID-19 is Changing the Approach for the Vaccine Development Process, Tim Schenk, Janssen Finland
Business Finland Update, Kari Klossner

Pitching Competition:
Finnadvance, Prateek Singh
PARKS, Patrik Hollos, Åbo Akademi University
LS CancerDiag, Philippe Arnez
TILT BioTherapeutics, Aino Kalervo
StemSight, Laura Koivusalo

Presentations can be found at

For more information about HealthBIO event, please contact Mr. Tero Piispanen at Turku Science Park Ltd.


Previous HealthBIO events:

HealthBIO 2019, 15-16 May

HealthBIO 2019 Seminar and Partnering Day

The HealthBIO 2019 Seminar programme covered highlights of the recent industry milestones and prospects for the future in Finland and Europe with international speakers as well as funding trends and success stories of fast-growing SMEs.  The presentations are uploaded below. The seminar day ended with a joint get together event for all Life Science Live attendees.

HealthBIO 2019 Partnering Day and Pitching Competition were hosted by Business Finland Personalized Health Program. Partnering arrangements were coordinated by EEN, European Enterprise Network, and there were 75 registered participants from 7 countries (including Finland), and 80 meetings were agreed.
Preethy Paul, representing Team Anison from Åbo Akademi University, won the exiting pitching competition. Congratulations to the team!

HealthBIO 2019 Programme

Presentations 2019:

Fried: AI Imperatives for a Changing World
Forsström:_HealthBIO 2019 Opening words_
Piispanen: Finnish biotech year 2018
Franklin: Are there any more traditional Venture Capitalists
Miving: How digital technologies will change the business
Haapalinna: The New Modalities Ecosystem Project what is there for me
Dudley: Creating Companies of Scale
Viita: How Business Finland can help drive innovation and international growth in Life Sciences

Good industry performance lifted spirits in the HealthBIO conference 2018

Arranged for the 12th time, the HealthBIO seminar attracted a record-high number of participants to the familiar venue, Conference Centre Mauno in Turku Science Park. More than 250 people signed up for the seminar on 5 September, the get-together event in the evening, and the following day’s partnering event.

“The atmosphere was positive and enthusiastic”, sums up Tero Piispanen, Director responsible for HealthTurku in Turku Science Park Ltd.

The enthusiasm stems from the success of the pharmaceutical and diagnostics sectors as well as health technology. Tero Piispanen’s review on the development during the past year showed that the value of exports of health technology from Finland rose to over 2.2 billion euros in 2017. At the same time, the value of pharmaceutical exports was at the previous year’s level at just over 1.6 billion euros.

“The most important markets of Finnish health technology are the EU countries and the USA. In Europe the key markets are Germany, France and Great Britain. There’s also growth in Russia with exports valued at 63 million euros last year”, Mr Piispanen says.

The review on the past year included figures indicating growth and development of business. A total of 12 new life science companies have been established since autumn 2017, five of them in the Turku region. The development work of many new drugs has made progress, and several companies have successfully acquired financing.

“Equity investments in non-listed life science companies increased last year both in Finland and the EU on the whole. The total sum for the EU stood at 1.5 billion euros, of which Finland’s share was around 30 million euros, or just under two per cent.”

Another piece of good news is the growth of crowd funding which is also visible in the field of health technology.

“The sum of crowd funding totalled 56 million euros and benefited Mobidiag Oy, ArcDia International Oy, Desentum Oy and Askel Healthcare which gathered nearly 10 million euros.”

German view to life science expertise in Turku and Finland

One of the interesting keynote speakers was Miriam Holstein, CEO of Bayer Nordic who started in her position a year ago. She is in charge of the North European operations of the company with a global turnover of 35 billion euros that employs nearly 100,000 people and spends annually 4.5 billion euros in R&D. She says that she has made herself at home in Finland and feels very welcome.

“I am impressed by the openness of influencing, the way to co-operate, the standard of digital services, and the innovativeness of the ecosystem. They make Finland unique.”

Ms Holstein says that her observations also apply to the company’s operating environment in Turku.

“The growth in the Turku region is the fastest in Finland. You can also see it at our Turku plant which is a good indicator on what is going on around us: inter-disciplinary co-operation, openness to new ideas, and focus on using them.”

Watch a video interview in which Miriam Holstein also reveals the secret of the success of the company’s intrauterine device Mirena which is made in Turku and sells for over one billion euros globally!

HealthBIO 2018 Program